Welcome to the UPF Digital Repository

EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

Show simple item record

dc.contributor.author Agache, Ioana
dc.contributor.author Akdis, Cezmi A.
dc.contributor.author Akdis, Mubeccel
dc.contributor.author Brockow, Knut
dc.contributor.author Chivato, Tomas
dc.contributor.author Del Giacco, Stefano
dc.contributor.author Eiwegger, Thomas
dc.contributor.author Eyerich, Kilian
dc.contributor.author Giménez Arnau, Anna Maria
dc.contributor.author Gutermuth, Jan
dc.contributor.author Guttman-Yassky, Emma
dc.contributor.author Maurer, Marcus
dc.contributor.author Ogg, Graham
dc.contributor.author Ong, Peck Y.
dc.contributor.author O'Mahony, Liam
dc.contributor.author Schwarze, Jürgen
dc.contributor.author Warner, Amena
dc.contributor.author Werfel, Thomas
dc.contributor.author Palomares, Oscar
dc.contributor.author Jutel, Marek
dc.date.accessioned 2022-05-05T07:40:56Z
dc.date.available 2022-05-05T07:40:56Z
dc.date.issued 2022
dc.identifier.citation Agache I, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, et al. EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy. 2022 Jan; 77(1): 17-38. DOI: 10.1111/all.15030
dc.identifier.issn 0105-4538
dc.identifier.uri http://hdl.handle.net/10230/52990
dc.description.abstract Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Wiley
dc.rights This is the peer reviewed version of the following article: Agache I, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, et al. EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy. 2022 Jan; 77(1): 17-38, which has been published in final form at http://dx.doi.org/10.1111/all.15030. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
dc.title EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1111/all.15030
dc.subject.keyword GRADE
dc.subject.keyword Chronic spontaneous urticaria
dc.subject.keyword Guidelines
dc.subject.keyword Omalizumab
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/acceptedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking